Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021)

Historic Notes Payables for Inhibikase Therapeutics (IKT) over the last 2 years, with Q4 2021 value amounting to $248911.0.

  • Inhibikase Therapeutics' Notes Payables fell 2197.03% to $248911.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $248911.0, marking a year-over-year decrease of 2197.03%. This contributed to the annual value of $248911.0 for FY2021, which is 2197.03% down from last year.
  • Latest data reveals that Inhibikase Therapeutics reported Notes Payables of $248911.0 as of Q4 2021, which was down 2197.03% from $248911.0 recorded in Q3 2021.
  • Inhibikase Therapeutics' Notes Payables' 5-year high stood at $1.2 million during Q1 2021, with a 5-year trough of $248911.0 in Q2 2021.